Stocktoria
Zoetis Inc. ZTS
Zoetis Inc. (ZTS) earns a Piotroski F-score of 5/9 (mixed financial health). It does not currently pay a dividend. FY2025 revenue was $9.5B at a 28.2% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -2.56 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-08-11 | Citigroup | Buy (main) |
| 2026-08-11 | BNP Paribas | Outperform (main) |
| 2026-08-10 | Piper Sandler | Neutral (main) |
| 2026-08-07 | UBS | Neutral (main) |
| 2026-08-07 | JP Morgan | Overweight (main) |
| 2026-08-06 | William Blair | Market Perform (down) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Forward estimates · earnings calendar →
Consensus analyst estimates and scheduled dates — forward-looking, may change.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 5/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| ZTS | Zoetis Inc. | 5/9 | — | 12.4 | +2.3% |
| BHC | Bausch Health Companies Inc. | 7/9 | -0.26 | 17.8 | +6.7% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | 4/9 | 7.5 | 29.1 | +8.9% |
| OGN | Organon & Co. | 5/9 | — | 19 | -2.9% |
| ONC | BeOne Medicines Ltd. | 7/9 | 1.78 | — | +40.2% |
| ELAN | Elanco Animal Health Inc | 6/9 | — | — | +6.2% |
| VTRS | Viatris Inc | 3/9 | 0.65 | — | -3% |
About Zoetis Inc.
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaborated with Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was incorporated in 2012 and is headquartered in Parsippany, New Jersey.
FAQ
Is ZTS financially healthy?
Zoetis Inc.'s Piotroski F-score is 5/9 (8–9 is excellent, 0–3 weak).
Does ZTS pay a dividend?
No, Zoetis Inc. does not currently pay a dividend.
How profitable is ZTS?
In FY2025, Zoetis Inc. had a net margin of 28.2% and a return on equity of 78.3%.
Is ZTS overvalued or undervalued?
Zoetis Inc. trades at about 12.2× trailing earnings — below its 10-year norm (10-year range 20.7×–46.8×, median 37.0×). Stocktoria reports the data, not buy/sell advice.
What is the analyst price target for ZTS?
The average Wall-Street price target for Zoetis Inc. is $100.94, about 37.3% above the recent price, from 16 analysts (consensus: buy).
Is ZTS a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Zoetis Inc.: a Piotroski F-score of 5/9, a P/E of about 12.4×. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.